106261-48-7

Basic information

• Product Name: 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid
• Synonyms: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)BENZOIC ACID;4-[(4-Methyl-1-piperaziny)methyl]benzoic acid dihydrochloride;Benzoic acid,4-[(4-methyl-1-piperazinyl)methyl]-;4-(4-Methyl-1-piperazinylMethyl)benzoic Acid;4-[(4-Methyl-1-piperaziny)Methyl]benzoic acid dihy;Imatinib Related Compound (4-(4-Methylpiperazin-1-yl)methyl)benzoic Acid);Imatinib-int G
• CAS NO: 106261-48-7
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• EINECS: 1312995-182-4
• Mol File: 106261-48-7.mol
• Article Data: 22

Chemical Properties

• Melting Point: 310-312 °C
• Boiling Point: 377.198 °C at 760 mmHg
• Flash Point: 181.923 °C
• Appearance: white crystalline powder
• Density: 1.175 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.31±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid(106261-48-7)
• EPA Substance Registry System: 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid(106261-48-7)

Safety Data

• Hazardous Substances Data: 106261-48-7(Hazardous Substances Data)

Usage

Description

4-(4-Methylpiperazin-1-ylmethyl)benzoic acid is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its molecular structure, which features a benzoic acid core with a 4-methylpiperazin-1-ylmethyl side chain. 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid is known for its potential applications in the pharmaceutical industry due to its ability to be incorporated into the development of new drugs.

Uses

Used in Pharmaceutical Industry:
4-(4-Methylpiperazin-1-ylmethyl)benzoic acid is used as a pharmaceutical intermediate for the development of Imatinib, a potent and selective inhibitor of certain tyrosine kinases. Imatinib is primarily used in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies. The compound's role as an intermediate allows for the creation of effective and targeted therapies for these conditions.
As an intermediate in the synthesis of Imatinib, 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid plays a vital role in the pharmaceutical industry. Its incorporation into the drug development process enables the creation of therapies that can effectively target and inhibit specific tyrosine kinases, leading to improved treatment options for patients suffering from various types of cancer.

InChI:InChI=1/C13H18N2O2/c1-14-6-8-15(9-7-14)10-11-2-4-12(5-3-11)13(16)17/h2-5H,6-10H2,1H3,(H,16,17)

Upstream product

• 314268-40-1 4-((4-methylpiperazin-1-yl)methyl)-benzoic acid methyl ester 
• 728936-43-4 4-(4-methylpiperazin-1-ylmethyl)benzoic acid methyl ester hydrochloride 
• 109-01-3 1-methyl-piperazine 
• 1642-81-5 p-(chloromethyl)benzoic acid 
• 619-66-9 4-Carboxybenzaldehyde 
• 1571-08-0 methyl 4-formylbenzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 314268-40-1 4-((4-methylpiperazin-1-yl)methyl)-benzoic acid methyl ester 
• 148077-69-4 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride 
• 945762-01-6 N-methoxy-N-methyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 
• 887399-39-5 4-(4-methyl-piperazin-1-ylmethyl)-N-[3-(2-oxo-2,3-dihydro-1H-indol-7-ylamino)-phenyl]-benzamide 
• 887399-45-3 4-(4-methyl-piperazin-1-ylmethyl)-N-[3-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-phenyl]-benzamide 
• 777054-54-3 methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-ethyl}-phenyl ester 
• 790299-79-5 masitinib 
• 152459-95-5 imatinib 
• 1190219-22-7 N,N'-(4,4'-(1,4-phenylene)bis(thiazole-4,2-diyl))bis(4-((4-methylpiperazin-1-yl)methyl)benzamide) 
• 1190219-29-4 N-[5-(2-chloro-4-pyridin-3-yl-phenyl)-thiazol-2-yl]-4-(4-methylpiperazin-1-ylmethyl)-benzamide 
• 1190219-66-9 N-[4-(9-Benzenesulfonyl-9H-carbazol-2-yl)-thiazol-2-yl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 

Relevant articles and documents

Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections

The recent Ebola epidemics in West Africa underscore the great need for effective and practical therapies for future Ebola virus outbreaks. We have discovered a new series of remarkably potent small molecule inhibitors of Ebola virus entry. These 4-(aminomethyl)benzamide-based inhibitors are also effective against Marburg virus. Synthetic routes to these compounds allowed for the preparation of a wide variety of structures, including a conformationally restrained subset of indolines (compounds 41-50). Compounds 20, 23, 32, 33, and 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Representative compounds (20, 32, and 35) have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9. These 4-(aminomethyl)benzamides are suitable for further optimization as inhibitors of filovirus entry, with the potential to be developed as therapeutic agents for the treatment and control of Ebola virus infections.

Application of N-substituted (aminomethyl)benzoate strategy in design of scutellarein derivatives with improved Caco-2 cell permeability and in vitro antioxidative activity

A series of 4′-N-substituted (aminomethyl)benzoate derivatives of scutellarein were designed and synthesized. Evaluation of their physiochemical properties showed that the designed target compounds 5a-e exhibit higher chemical stability and aqueous solubility than scutellarin and scutellarein. The permeability (Papp AP to BL) of 5c-e in Caco-2 cells were 2.8, 8.1, and 12.6 times higher than that of scutellarin and 1.3, 4.1, and 6.0 times higher than that of scutellarein; especially, 5e had the highest Papp AP to BL value (7.19 ± 0.31 × 10-6 cm/s) and the lowest ER (Papp BL to AP/Papp AP to BL) value of 0.17. In vitro antioxidative evaluation results revealed that 5e could protect against H2O2-induced PC12 cells' oxidative damage by attenuating mitochondrial membrane potential loss and decreasing H2O2-induced reactive oxygen species (ROS) production.

N-phenyl-2-pyrimidine-amine derivatives

The present invention relates to novel amides and a process for preparing these amides.

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

The present invention provides compounds for the prevention or treatment of cancer or a bacterial or viral infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the prevention or treatment of cancer or a bacterial or viral infection in a subject.